Oligonucleotides moving from rare drug provision to wider population usage can be underpinned by affordable phosphoramidite provision. A bold statement becomes real with the 2021 approval of Inclisiran, used for the treatment of cardiovascular disease. A breadth of common diseases, including cardiovascular disease, oncology and metabolic disorders will respond to Oligonucleotide drug provision. Oligonucleotides because … Continue reading Oligonucleotide stars of the future can be underpinned by the superb Amideus brand from Primopus AG.